TFCP2L1 and breast cancer: In BC patients, activation of the CDK1‐TFCP2L1 cascade is associated with aggressive high‐grade tumors, lymphovascular invasion (LVI), muscularis propria invasion, frequent metastasis to distant organs, and low patient survival rates.